Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term

Zacks Investment Research advocates its proprietary Zacks Rank and Style Scores (Value, Growth, Momentum, VGM) for identifying strong investment opportunities, citing that Zacks #1 (Strong Buy) stocks have delivered an average annual return of +23.62% since 1988. Utilizing this methodology, Catalyst Pharmaceutical (CPRX), a commercial-stage biopharmaceutical company, is designated a #2 (Buy) with an "A" VGM Score and "B" Growth Score. This favorable outlook is underpinned by a forecasted 1.8% year-over-year earnings growth, recent upward revisions by four analysts for fiscal 2025 to a $2.25 per share consensus estimate, and a historical average earnings surprise of +28.2%, positioning CPRX as a notable growth prospect.

Analysis

Catalyst Pharmaceutical (CPRX), a commercial-stage biopharmaceutical company focused on rare diseases, has been identified as a strong candidate for growth investors based on the Zacks Investment Research rating system. The company holds a Zacks Rank of #2 (Buy), a composite VGM Score of 'A', and a Growth Style Score of 'B'. This positive quantitative assessment is supported by several forward-looking indicators. Analyst sentiment for fiscal 2025 is improving, with four analysts revising earnings estimates upward over the last 60 days, raising the Zacks Consensus Estimate by $0.10 to $2.25 per share. However, the forecasted year-over-year earnings growth for the current fiscal year is a modest 1.8%. This is counterbalanced by a strong track record of operational outperformance, as evidenced by an average positive earnings surprise of +28.2%, suggesting a history of exceeding market expectations.

Key Decisions for Investors

• Given the 'Buy' rating, high quantitative scores, and positive fiscal 2025 analyst revisions, growth-oriented investors may view this as a signal to consider CPRX for their portfolio.
• Investors should closely monitor upcoming earnings reports to validate that the growth trajectory is accelerating towards the more optimistic 2025 consensus, as the current fiscal year's forecasted growth of 1.8% is minimal.
• While the Zacks analysis is positive, it is based on a proprietary model, and prudent investors should supplement this with fundamental due diligence on the company's drug pipeline and competitive positioning within the rare disease market.